Comparison of the pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (muzolimine).
In a biometrically planned, double-blind study on 12 Oedema-free male patients the saluretic effect of muzolimine 30 mg was compared with furosemide 40 mg. The plasma level of muzolimine was determined and correlated with its pharmacodynamics. In terms of excretion during the 12-hour observation period muzolimine 30 mg had as great a cumulative effect as furosemide 40 mg. There was a significant difference in the time-response curve. During the first gwo hours furosemide 40 mg had more saluretic effect than muzolimine 30 mg. Between two and four hours there was no significant difference between the two substances. Between four and six hours, however, muzolimine was somewhat more effective than furosemide, although the difference did not reach the level of significance. After 6 h there was no longer any difference between the two compounds. The half-life of the fall in concentration of muzolimine in plasma was 3.7 up to 10 h after its administration. The time-response curve of the increased urine excretion correlated well with the time course of the concentration of muzolimine in plasma.
D000328:Adult; D004231:Diuresis / Q000187:drug effects; D004232:Diuretics / Q000378:metabolism / Q000494:pharmacology*; D004311:Double-Blind Method; D004573:Electrolytes / Q000652:urine; D005665:Furosemide / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008297:Male; D011720:Pyrazoles / Q000378:metabolism / Q000494:pharmacology*; D013997:Time Factors
D004232:Diuretics; D004573:Electrolytes; D011720:Pyrazoles; D005665:Furosemide